Florence Joulain

Chilly, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Letter to the editor regarding "Cost-effectiveness of benralizumab versus mepolizumab and dupilumab in patients with severe uncontrolled eosinophilic asthma in Spain".

Letter to the editor regarding "Cost-effectiveness of benralizumab versus mepolizumab and dupilumab in patients with severe uncontrolled eosinophilic asthma in Spain".

Journal: The Journal of asthma : official journal of the Association for the Care of Asthma

Published: September 21, 2024

Modeling severe uncontrolled asthma: Transitioning away from health states.

Modeling severe uncontrolled asthma: Transitioning away from health states.

Journal: Contemporary clinical trials communications

Published: July 01, 2024

Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK.

Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK.

Journal: Journal of asthma and allergy

Published: December 13, 2023

Epidemiology of Childhood Asthma in the UK.

Epidemiology of Childhood Asthma in the UK.

Journal: Journal of asthma and allergy

Published: December 13, 2023

Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan.

Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan.

Journal: The Journal of asthma : official journal of the Association for the Care of Asthma

Published: November 09, 2021

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.

Journal: Targeted oncology

Published: December 27, 2015

Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer

Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer

Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

Published: August 20, 2014

Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the United Kingdom and the Netherlands.

Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the United Kingdom and the Netherlands.

Journal: International journal of colorectal disease

Published: July 16, 2014

A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI.

A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI.

Journal: BMC cancer

Published: December 11, 2013

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.

Journal: British journal of cancer

Published: February 22, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026